CGIM
MRVI icon

Cannon Global Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Cannon Global Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71,000
Closed -$590K – 87
2024
Q3 		$590K Buy
+71,000
New +$614K 0.94% 29
2023
Q3 		– Sell
-15,800
Closed -$196K – 42
2023
Q2 		$196K Buy
+15,800
New +$213K 1.02% 31

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cannon Global Investment Management's MRVI Position: Q4 2024 in Review

Cannon Global Investment Management sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 71,000 shares — an estimated $590K sold.

Cannon Global Investment Management first reported a position in MRVI in Q2 2023 and held it in 2 quarters. The position peaked at $590K in Q3 2024. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

  • Cannon Global Investment Management reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
  • Cannon Global Investment Management sold 71,000 Maravai LifeSciences shares in Q4 2024, an estimated $590K.
  • Cannon Global Investment Management first reported a position in Maravai LifeSciences in Q2 2023 and held it in 2 quarters.
  • Cannon Global Investment Management's Maravai LifeSciences position peaked at $590K in Q3 2024.
  • 185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Cannon Global Investment Management's 13F filing for Q4 2024, filed 11 Feb 2025.